BOEUF Stock Chart & Stats
$23.58
-$1.04(-4.34%)
At close: 4:00 PM EDT
$23.58
-$1.04(-4.34%)
Day’s Range― - ―
52-Week Range$17.66 - $33.74
Previous CloseN/A
Volume116.00
Average Volume (3M)250.00
Market Cap
$1.47B
Enterprise Value$13.69K
Total Cash (Recent Filing)$434.31M
Total Debt (Recent Filing)$10.13M
Price to Earnings (P/E)68.4
Beta0.57
Next Earnings
Oct 22, 2026EPS Estimate
0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.24
Shares Outstanding65,859,190
10 Day Avg. Volume200
30 Day Avg. Volume250
Financial Highlights & Ratios
PEG Ratio14.80
Price to Book (P/B)14.28
Price to Sales (P/S)10.54
P/FCF Ratio57.29
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.51
Revenue Forecast (FY)$156.68M
Bulls Say, Bears Say
Bulls Say
High-growth OutlookReiterated guidance in the 33–36% range indicates strong expected demand for CERAMENT and supports continued expansion over the next several quarters. Growth across the U.S. and EUROW markets suggests the opportunity is broadening beyond a single geography or isolated product event.
Scalable ProfitabilityVery high gross margins and a 29% adjusted operating margin demonstrate substantial economic value in the CERAMENT platform and operating leverage as sales scale. This profitability provides resources to fund commercial expansion while preserving resilience if growth moderates.
Financial Flexibility And Cash GenerationMinimal leverage materially reduces financial risk and leaves management flexibility to invest in product development, market expansion, and commercial capacity. Strong recent free cash flow also indicates that reported profitability is converting into internally generated funding for future growth.
Bears Say
Growth Is DeceleratingAlthough current growth remains solid, the slowdown from earlier hyper-growth levels means future expansion may require increasing commercial investment and broader adoption. Deceleration can make it harder to sustain operating leverage and raises the importance of execution across newer markets.
Rising Commercial And Incentive CostsHigher selling, marketing, commission, and incentive costs can limit the conversion of strong revenue growth into reported operating profit. If these expenses remain elevated as the company expands its sales footprint, margin progression may be slower than the underlying gross margin suggests.
Regulatory And Reimbursement UncertaintyUncertain approval, reimbursement, and clinical-publication timelines could delay adoption of important growth opportunities and make commercialization planning less predictable. The company has not included CERAMENT V sales in guidance, limiting near-term visibility on these potential drivers.
BONESUPPORT HOLDING AB News
BOEUF FAQ
What was BONESUPPORT HOLDING AB’s price range in the past 12 months?
BONESUPPORT HOLDING AB lowest stock price was $17.66 and its highest was $33.74 in the past 12 months.
What is BONESUPPORT HOLDING AB’s market cap?
BONESUPPORT HOLDING AB’s market cap is $1.47B.
When is BONESUPPORT HOLDING AB’s upcoming earnings report date?
BONESUPPORT HOLDING AB’s upcoming earnings report date is Oct 22, 2026 which is in 37 days.
How were BONESUPPORT HOLDING AB’s earnings last quarter?
BONESUPPORT HOLDING AB released its earnings results on Jul 16, 2026. The company reported $0.129 earnings per share for the quarter, beating the consensus estimate of $0.119 by $0.011.
Is BONESUPPORT HOLDING AB overvalued?
According to Wall Street analysts BONESUPPORT HOLDING AB’s price is currently Overvalued.
Does BONESUPPORT HOLDING AB pay dividends?
BONESUPPORT HOLDING AB does not currently pay dividends.
What is BONESUPPORT HOLDING AB’s EPS estimate?
BONESUPPORT HOLDING AB’s EPS estimate is 0.14.
How many shares outstanding does BONESUPPORT HOLDING AB have?
BONESUPPORT HOLDING AB has 65,859,190 shares outstanding.
What happened to BONESUPPORT HOLDING AB’s price movement after its last earnings report?
BONESUPPORT HOLDING AB reported an EPS of $0.129 in its last earnings report, beating expectations of $0.119. Following the earnings report the stock price went down -6.764%.
Which hedge fund is a major shareholder of BONESUPPORT HOLDING AB?
Currently, no hedge funds are holding shares in BOEUF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BONESUPPORT HOLDING AB
Bonesupport Holding AB (publ) is an orthobiologics company that specializes in the development and commercialization of injectable bioceramic bone graft substitutes. These products are utilized for treating bone voids and are available internationally, including in Europe and North America. Among its key offerings are CERAMENT Bone Void Filler, a synthetic, injectable, moldable, and drillable solution comprising hydroxyapatite, calcium sulfate, and the radio-contrast agent iohexol. Additionally, the company provides CERAMENT G, an injectable ceramic bone graft substitute infused with gentamicin, and CERAMENT V, a synthetic bone void filler containing vancomycin. Bonesupport is also advancing preclinical product candidates focused on promoting bone regrowth. These future solutions are being developed for applications such as trauma, revision arthroplasty, chronic osteomyelitis, oncology, and bone and foot infections related to diabetes. Founded in 1999, the company maintains its headquarters in Lund, Sweden.
BOEUF Company Deck
BOEUF Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a predominantly positive operational and financial picture: strong revenue growth (30% FX-adjusted), high adjusted margins (29%), solid cash generation and pronounced U.S. launch momentum for CERAMENT G. Material positives include regulatory progress, proposed CMS reimbursement improvements, and healthy EUROW performance. Headwinds include a small set of U.S. accounts temporarily restricting usage (modestly dampening growth), higher commercial and incentive costs, minor gross margin impacts from write-downs and tariffs, and uncertainty around the timing of regulatory approvals and study publications. On balance the company's growth trajectory and scalable profitability outweigh the transitory challenges discussed.View all BOEUF earnings summariesTechnical Analysis
Ownership Overview
―
Insiders
8.49% Mutual Funds
― Other Institutional Investors
86.42% Public Companies and
Individual Investors